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Tat activates transcription by interacting with Sp1,
NF-B, positive transcription elongation factor b, and
trans-activator-responsive element (TAR). Tat and Sp1
play major roles in transcription by protein-protein in-
teractions at human immunodeficiency virus, type 1
(HIV-1) long terminal repeat. Sp1 activates transcrip-
tion by interacting with cyclin T1 in the absence of Tat.
To disrupt the transcription activation by Tat and Sp1,
we fused Sp1-inhibiting polypeptides, zinc finger
polypeptide, and the TAR-binding mutant Tat (TatdMt)
together. A designed or natural zinc finger and Tat mu-
tant fusion was used to target the fusion to the key
regulatory sites (GC box and TAR) on the long terminal
repeat and nascent short transcripts to disrupt the mo-
lecular interaction that normally result in robust tran-
scription. The designed zinc finger and TatdMt fusions
were targeted to the TAR, and they potently repressed
both transcription and replication of HIV-1. The Sp1-
yinhibiting POZ domain, TatdMt, and zinc fingers are
key functional domains important in repression of tran-
scription and replication. The designed artificial zinc
fingers were targeted to the high affinity Sp1-binding
site, and by being fused with TatdMt and POZ domain,
they strongly block both Sp1-cyclin T1-dependent tran-
scription and Tat-dependent transcription, even in the
presence of excess expressed Tat.
More than 35 million people worldwide are infected with
HIV,1 and most of them will develop AIDS (Ref. 1 and refer-
ences therein). A mixture of reverse transcriptase and protease
inhibitors can reduce the amount of HIV in the blood signifi-
cantly. However, the severe side effects of these drugs, expen-
sive cost, and viral mutation make the chemotherapy less than
satisfactory. The rapid development of alternative therapies
such as DNA vaccines carrying HIV genes, designed zinc fin-
ger, and RNA interference remains critically important (Ref. 2
and references therein).
The molecular mechanism of the regulation of HIV-1 tran-
scription provides a molecular basis for developing novel anti-
viral agents. There is a great need for developing therapeutic
agents that can repress transcription of the HIV-1 to overcome
the problem viral resistance, because such agents would pre-
vent production of the genetic material for viral replication and
the template for reverse transcriptase. Because Sp1 and Tat
(trans-activator protein) play a central role in the transcrip-
tion, inhibition of both Sp1 and Tat can repress transcription
and replication of HIV-1 (3).
Zinc finger domains are small DNA-binding modules (about
30 a.a.) that can be engineered to bind to the desired target
sequences (4–6). Recently, the engineered zinc finger or its
fusion form with other functional domains have been con-
structed by several groups, including our group, and these zinc
fingers have successfully activated or repressed gene targets in
various systems including the HIV-1 viral gene (Refs. 2, 7, and
8 and references therein). In the case of HIV-1, the engineered
zinc finger proteins were designed to bind a key regulatory
DNA sequence within the HIV-1 LTR promoter, including Sp1
sites, the TATA box, and the downstream sequences (2, 7, 8).
They were even more effective when linked with the repression
domain of the SID or KRAB transcription repressors (2, 8). The
zinc finger proteins have the potential to exploit several HIV-
specific processes, both at the level of transcription at the
promoter and also at other nucleic acid-protein interactions
such as TAR-Tat interaction. HIV-1 encodes a regulatory pro-
tein Tat, which functions by interaction with the specific RNA
element called TAR. The protein-RNA interactions are abso-
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lutely required for HIV replication and transcription, and so
they are enticing potential target points for antiviral strate-
gies. No studies using zinc finger proteins have yet targeted the
Tat-TAR interaction.
The POZ domain of FBI-1 has recently been shown to bind to
the zinc finger DNA-binding domain of Sp1 to prevent the
recognition of the target GC boxes and thus to repress tran-
scription activation (9). FBI-1 has both zinc fingers recognizing
the LTR inducer of short transcript sequences and Sp1-inhib-
iting POZ domain. In addition, FBI-1 was shown to interact
with Tat via its zinc finger and to form an inducer of short
transcript-FBI-1-Tat-P-TEFb complex in vivo, which suggested
that the FBI-1 protein is in close contact with other regulatory
proteins and nucleic acids (10, 11).
Initially, we designed transcription repressors that incorpo-
rated part or the full length of FBI-1. In addition to the unique
features of the FBI-1, we incorporated a novel feature of the
TatdMt, the dominant negative mutant form of Tat, for targeting
the Tat-TAR interaction. This particular form of the Tat mutant
can bind TAR efficiently, but it is lacking the ability to form
P-TEFb (12). FBI-1 or POZ-TatdMt fusions can target both the
Sp1 and Tat-TAR interaction, and so they are effective transcrip-
tion blockers. By structural analysis of the fusion gene construct
FBI-1-TatdMt, we mapped the functional domains important in
transcription repression. Furthermore, we designed artificial
zinc finger (AZF) fusions specifically targeting the Sp1-binding
GC box region and Tat-TAR interaction. The TatdMt fusion pro-
teins of ZFs were efficiently targeted to the HIV-1 LTR and
strongly repressed transcription and replication.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies—The HIV-1 LTR-CAT fusion plasmid
(pU3R-IIICAT or luciferase) has been described previously (13). The
expression plasmids for TatWt (HIVHBX2R type, 86 a.a.), TatdMt
(Tat K28A, K50A, 72 a.a.), and FBI-1 were prepared by subcloning
their cDNAs into pcDNA3.0 (Invitrogen) (12–14). The mammalian
expression plasmids for FBI-1 or POZ domain fusion proteins with a
mutant TatdMt were constructed by subcloning their cDNAs into
pcDNA3.0-TatdMt plasmid (FBI-1, GenBankTM accession number,
AF097916). The pG5-luciferase was from Promega, and the pG5-Sp1-
luciferase was prepared by subcloning five copies of the Sp1-binding GC
box into the pG5-luciferase. pBind Gal4-POZFBI-1, and -FBI-1 were
prepared by subcloning the cDNA into the pBind plasmid (Promega).
All of the constructs were verified by sequencing.
Cell Culture and Transient Transfection Assays—To analyze the
repression by Gal4-POZ domain or FBI-1 fusions on Sp1-dependent
transcription, CV-1 cells were transfected with a mixture of pG5-Luc or
pG5-Sp1-luc plasmid (0.4 g), pCMV-LacZ plasmid (0.2 g), and vari-
ous pGal4-POZFBI or pGal4-FBI (0.4 g) by using Lipofectamine Plus
(Invitrogen). To assay the repression caused by various fusion proteins
on HIV-1 transcription, the stable HeLa cells integrated with the HIV-1
LTR-CAT gene (pU3R-III CAT) were transfected with the pcDNA3.0
TatWt expression plasmid (0.3 g) and various pcDNA3.0 TatdMt fu-
sion expression plasmids (0.3 g). For the titration experiments, 0–0.3
g of pcDNA3.0 expression plasmids for FBI-1-TatdMt was cotrans-
fected with pcDNA3.0 TatWt (0.3 g) into stable HeLa cells. The cells
were grown for 24 h and then assayed for reporter gene expression.
Variations in transfection efficiencies were normalized using coex-
pressed -galactosidase activity.
HIV-1 Replication Inhibition Analysis—Transient trans-complemen-
tation or a single-round HIV-1 replication inhibition analysis was car-
ried out as described elsewhere (15–18). A plasmid that expresses the
HIV-1 genome with the hygromycin B resistance gene was cotrans-
fected into 293T cells with a viral envelope protein VSV-G expression
plasmid and either the control (pHYK) or the TatdMt fusion protein
expression plasmid. The cotransfection resulted in the production of
HIV-1 virus particles that undergo only a single round of infection in
susceptible cell lines such as HeLaT4 and Magi cells (15–18). The
efficiency of a single round of infection was determined by scoring the
numbers of HygR HeLaT4 cells or -galactosidase-positive Magi cells
(see Fig. 2A). To produce HIV-1 virus, 293T cells were transfected with
HIV-1 proviral DNA (YK177–86, 1 g) (16), and either the control
(pHYK, 2 g) or TatdMt fusion expression plasmid (fused with POZ
domain, FBI-1, artificial zinc finger, 2 g), the envelope protein expres-
sion plasmid (pVSV-G, 0.5 g), and the LacZ gene expression plasmid
(MFG/LacZ/Puro, 0.5 g) using Lipofectamine Plus. The MFG/LacZ/
Puro plasmid was cotransfected to normalize variations in transfection
efficiencies. The transfected cells were further incubated for 2 days to
prepare a supernatant containing infectious HIV-1 virus particles. The
supernatant from the transfected 293T cells was collected, filtered,
diluted serially, and used to infect CD4 HeLaT4 cells or Magi cells
(HeLaT4 cells integrated with the HIV-1 LTR-LacZ gene). After 4 h,
fresh culture medium was then added, and the cells were cultured for
selection of HygR-positive cells, and the virus titer was determined by
counting the colonies that were fixed and stained with 0.5% crystal
violet/50% (v/v) methanol. In the case of Magi cells, the virus titer was
determined by scoring the number of Magi cells that turned blue after
-galactosidase staining. The assays results are presented as averages
of three independent experiments.
Mapping of Functionally Important Functional Domains of FBI-1-
TatdMT Fusion—Various deletion and zinc finger mutants of FBI-1
were prepared by subcloning FBI-I or FBI-1 zinc finger 1 mutant cDNA
fragments that had gone through PCR into the pcDNA3.0-TatdMt plas-
mid (see Fig. 3A) (9, 11). For the PCR to amplify the region between a.a.
124 and 584 for the constructs 2-1 and 2-2 (see Fig. 3A), 5-ACGTAA-
GCTTACCATGGCGCCGACCTCCTGGACCGG-3 (forward) and 5-G-
ATCGAATTCGGCGAGTCCGGCTGTGAAGTT-3 (reverse) were used.
To amplify the region between a.a. 124 and 512 for the constructs 3-1
and 3-2, 5-ACGTAAGCTTACCATGGCGCCGACCTCCTGGACCGG-3
(forward) and 5-GATCGAATTCCGGGCTGGGGTCGGGCGCCCCGC-
C-3 (reverse) were used. Also, for the PCR between a.a. 335 and 584
(for 4-1 construct) or a.a. 512 (for 51 and 5-2 constructs), 5-ACGTA-
AGCTTACCATGGGGGACAGCGACGAGTC-3 (forward) was paired
with reverse primer (5-GATCGAATTCGGCGAGTCCGGCTGTGAAG-
TT-3 or 5-GATCGAATTCCGGGCTGGGGTCGGGCGCCCCGCC-3).
For the 4–1ZFC, forward primer (5-ACGTAAGCTTACCATGGGGGA-
CAGCGACGAGTC-3) was paired with reverse primer (5-GATCGAA-
TTCGGCGAGTCCGGCTGTGAAGTT-3) for the PCR. For the PCR of
ZF (a.a. 371–495), forward primer (5-ACGTAAGCTTACCATGGAGA-
AGGTGGAGAAGATCCGA-3) and reverse primer (5-ACGTAAGCTT-
CGAGGGGACGCCGTTGCAGCC-3) were used.
PCR was performed by denaturing at 94 °C for 5 min and 30 cycles of
an amplification reaction (94 °C 30 s, 60 °C 1 min, 72 °C 3 min), and a
final extension was done at 72 °C for 4 min. For PCRs to prepare
constructs 1-1, 2-1, 3-1, 4-1, 5-1, 4-1ZFC, and ZF fragments, we used the
FBI-1 cDNA that we isolated previously as a PCR template (9). For
PCRs of 2-2, 3-2, and 5-2, we used the FBI-1 cDNA with a mutation at
the first zinc finger (C384A,C387A) (11). The amplified PCR products
were cloned into the pcDNA3.0TatdMt/HindIII-EcoRI plasmid to gen-
erate various deletion mutants of FBI-1-TatdMt. ZF cDNA of FBI-1 that
had gone through PCR was prepared in the same manner and cloned
into pcDNA3.0 HindIII.
Design and Preparation of AZFs Recognizing Various Regions of
HIV-1 LTR—Ten AZFs that recognize the HIV-1 LTR were prepared by
a method previously described and cloned in pcDNA3.1 (4). The AZFs
contain three or four zinc fingers and recognize a 9- or 12-bp target
sequence, respectively. ZF-56-II is a four-zinc finger polypeptide, and
all others are three zinc fingers. The numbers are the uppermost
nucleotides of the recognition sites. These AZFs were designed to rec-
ognize the regions around Sp1-binding sites, TATA box, and a down-
stream region that are critical in the transcription of HIV-1 LTR. All of
the AZFs contain HA tag at the N terminus and nuclear localization
sequence fused with the zinc finger open reading frame. The AZF
expression vectors contain the same 5 and 3 sequences flanking the
AZF open reading frame.
To prepare the pcDNA3.0-artificial zinc finger fusion TatdMt
constructs, 5-GATCGGTACCATGGAATTGCCTCCAAAAAAGAAG-3
(forward) and 5-GATCGATATCTGCGGCCGCTTTTTCACCGGTA-
TG-3 (reverse) were used to subject the zinc finger open reading frame
sequences to PCR using various artificial zinc finger plasmids as PCR
templates. PCR was performed by denaturing at 94 °C for 5 min, 30
cycles of amplification reaction (94 °C for 30 s, 60 °C for 1 min, and
72 °C for 3 min), and a final extension at 72 °C for 4 min. The PCR
products were digested with HindIII and EcoRV and then cloned into
the pcDNA3.0-TatdMt plasmid that was digested with HindIII-EcoRV.
Electrophoretic Mobility Shift Assays (EMSA) of AZFs and Specificity
of AZF Binding—For EMSA, HA-AZF LTR-62 and HA-AZF LTR-65
polypeptides were prepared using TNT in vitro transcription and trans-
lation system (Promega, Madison, WI). Antibody against HA polypep-
tide was purchased from Upstate Biotechnology, Inc. Sp1 was pur-
chased from Promega. Oligonucleotide probes used are (only top strand
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shown): for Sp1 binding, 5-GATCATTCGATCGGGGCGGGGCGAGC-
3; for HA-AZF LTR-62, 5-GATCATTCGATCCGGGACTGGCGAGC-3;
and for HA-AZF LTR-65, 5-GATCATTCGATCGGGCGGGACGCAGC-
3. EMSA was carried out as described previously (9). To show that the
AZFs act specifically on their own target sequences and do not act on
the Sp1 binding GC box, two well characterized Sp1-dependent human
gene promoters fused with reporter luciferase gene, pADH5/FDH-luc
and p21Waf/cip1-luc, were cotransfected with AZF expression vectors into
HeLa cells and analyzed as described above under “Cell Culture and
Transient Transfection Assays.”
Transcription Inhibition Assays with the Artificial Zinc Fingers or
Artificial Zinc Fingers Fused with POZ Domain or TatdMt and Tran-
sient Transfection Reporter CAT Assays—To investigate the transcrip-
tion inhibition by the artificial zinc fingers proteins, the stable HeLa
cells integrated with the HIV-1 LTR CAT gene were grown in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal bovine
serum and penicillin (100 units/ml)/streptomycin (100 g/ml) (Invitro-
gen). After growing the cells for 24 h, the cells were transiently trans-
fected with 0.3 g of each pcDNA 3.1 zinc finger expression plasmid, 0.3
g of pcDNA3.0-TatWt expression plasmid, and 0.1 g of pCMV--
galactosidase (LacZ) mixed with Lipofectamine Plus (Invitrogen), and
the cells were then allowed to grow for 24 h. The rest of the assay
procedures are the same as described above in the transient transfec-
tion reporter assays.
To investigate whether the transcription activation by Sp1 and Cy-
clinT1 can be inhibited by the artificial zinc fingers and the AZFs fused
with POZ domain and TatdMt, the stable HeLa cells were transfected
with a plasmid mixture composed of 0.3 g of pcDNA3.0 AZF LTR-65 or
AZF LTR-65-TatdMt, in the presence or absence of 0.3 g of pCMV-Sp1
and/or cyclin T1, and 0.1 g pCMV--galactosidase (LacZ) using Lipo-
fectamine Plus. The rest of the transcription assay procedures are the
same as described above.
RESULTS
TatdMt fusion protein can potently represses transcription of
HIV-1—FBI-1 has been shown to bind to the zinc finger DNA-
binding domain of Sp1, to prevent Sp1 from recognizing the
target GC boxes, and to repress transcription activation by Sp1
(9). We tested whether Gal4DBD fusion proteins with FBI-1 or
the POZ domain of FBI-1 could repress transcription activation
by Sp1 when these proteins were targeted proximal to the GC
boxes. Targeting Sp1-inhibiting polypeptides using Gal4-DBD
proximal to the Sp1 binding GC box can effectively repress
transcription by more than 75% (Fig. 1, A and B). We applied
this finding for the control of HIV-1 transcription. Instead of
Gal4DBD, we used TatdMt (72 a.a. Tat K28A,K50A), a mutant
form of TAR RNA-interacting polypeptide Tat that lacks the
ability to interact with P-TEFb but binds efficiently to TAR
(12). The two lysine residues at a.a. 28 and 50 that are critical
in the interaction with cyclin T1 were replaced with alanines in
TatdMt. TatdMt neither forms a complex with P-TEFb (cyclin
FIG. 1. Targeting the Sp1-inhibiting polypeptides proximal to Sp1-binding GC boxes potently represses transcription. A, structures
of Gal4 UAS or UAS-5x(GC)-luciferase reporter plasmids. B, pG5-Luc with no Sp1-binding GC box sites shows minimal promoter activity.
Endogenous Sp1 potently activates transcription by more than 95-fold by binding to the GC boxes of pG5–5x(GC)-Luc. The coexpression of
Gal4-POZ or FBI-1 fusion potently represses transcription. UAS, upstream activator sequences of binding sites for Gal4 fusion proteins. GC-box,
Sp1-binding site. C, structures of TatdMt fusion polypeptides. D, transient transfection assays and transcription repression by TatdMt and its
fusions in stable HeLa cells integrated with HIV-1 LTR. , transient transfection in the absence of TatWt. f, assays in the presence of TatWt. E,
titration of transcription repression by FBI-1-TatdMt fusion. FBI-1-TatdMt competed with TatWt and potently inhibited transcription activation
by TatWt. The average of three independent assays is shown. The error bars represent the standard deviations.
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T1 and cyclin-dependent protein kinase 9) nor activates tran-
scription. These features of TatdMt can be useful in targeting
Sp1-inhibiting polypeptides to HIV-1 LTR. TAR-bound Tat is in
close proximity to and interacts with cellular proteins such as
Sp1, NF-B, general transcription factors (TFIID and TFIIH),
and P-TEFb (1, 3, 14, 19).
We fused the Sp1-inhibiting POZ domain and FBI-1 with
either the N or C terminus of TatdMt (72 a.a.) (Fig. 1C shows
the constructs in one configuration). The fusion expression
plasmids were transfected into stable HeLa cells with the in-
tegrated HIV-1 LTR-CAT gene in the presence or absence of
TatWt expression. In the absence of TatWt, transcription in the
stable HeLa cells occurred at a low basal level (Fig. 1D, lane 1).
TatWt potently activated the transcription of HIV-1 LTR by
46-fold (Fig. 1D, lane 1, filled bar). In contrast, TatdMt or
TatdMt fusions alone did not activate transcription over the
basal level (Fig. 1D, open bars, compare lanes 1 and lanes 2–4).
However, TatdMt reduced transcription activation by TatWt to
half of that observed with TatWt alone, and this suggested that
TatdMt competes with TatWt for TAR (Fig. 1D, compare lanes
1 and 2, filled bars). The TatdMt fusions successfully competed
with TatWt for TAR and potently repressed transcription (Fig.
1D, compare filled bars, lanes 1 versus lanes 3 and 4). FBI-1-
TatdMt was the most potent repressor, and it repressed tran-
scription down to the basal transcription level even in the
presence of an excess of TatWt expression plasmid (0.3 g) (Fig.
1D, filled bar, lane 4). The POZ domain (120 a.a.) is mainly
responsible for the repressor activity of the FBI-1-TatdMt fu-
sion. A titration experiment shows that FBI-1-TatdMt com-
peted with TatWt and potently inhibited transcription by 30%
at 3 ng and 80% at 30 ng, and it nearly nullified transcription
at 300 ng (Fig. 1F).
FBI-TatdMt Fusion Protein Potently Represses HIV-1 Repli-
cation—We investigated whether TatdMt fusion proteins can
inhibit HIV-1 replication by using transient trans-complemen-
tation assays in 293T cells (Fig. 2A) (15–18). The FBI-1-TatdMt
in the configuration, as shown in Fig. 3A, reduced the number
of infectious HIV-1 virus particles by 286-fold (Fig. 2B).
Mapping of Functional Domains of FBI-1-TatdMT Fusion—
Encouraged by the above finding, we investigated which do-
mains of FBI-1-TatMt fusion contribute to this potent tran-
scription repression. We prepared various deletion and
mutation constructs (Fig. 3A). Deletions were made within the
POZ domain (1–123 a.a.), C terminus (513–584 a.a.), and junc-
tional domain between the POZ domain and the zinc fingers
(124–334 a.a.). In addition, to investigate the importance of the
zinc finger DNA-binding domain, mutations at the two cysteine
residues of the first zinc finger (C384A and C387A) were intro-
duced (11). Transient transfection assays in the stable HeLa
cells with integrated HIV-1 LTR-CAT showed that the FBI-
TatdMt again potently repressed transcription activation by
TatWt (Fig. 3B, compare lanes 2 and 3). Deletion of the POZ
domain (construct 2-1) resulted in 5-fold decrease in transcrip-
tion repression, suggesting the importance of the domain in
repression by inhibiting Sp1 (Fig. 3B, compare lanes 3 and 4).
Although deletion of the POZ domain decreased the repres-
sion potential of the fusion proteins, the truncated fusions
containing zinc fingers and TatdMt still retained a significant
repression potential. All of the zinc finger mutants (constructs
2-2, 3-2, and 5-2) showed no repressor activity comparable with
any of the deletion mutants. They showed repression activity
that was only comparable with TatdMt alone (Figs. 3B and 1E).
This data suggested that the zinc finger is essential in tran-
scription repression of the fusion constructs, and this probably
happens by blocking transcription initiation or progression and
by helping TatdMt in TAR binding. Our data indicated that the
POZ domain and the zinc finger are the important repression
domains of FBI-1-TatdMt. The zinc finger itself, with no nu-
clear localization sequence attached, was able to repress tran-
scription, although relatively weakly compared with either
FIG. 2. FBI-TatdMt fusion protein
potently represses HIV-1 replication.
A, schematic diagram of HIV-1 replica-
tion inhibition assay. HIV-1 proviral
DNA, YK177–86, was cotransfected with
an envelope protein VSV-G expression
plasmid and the control pHYK plasmid or
the effector TatdMt fusion plasmids into
293T cells. Cell-free medium was col-
lected, diluted, and used to infect HeLaT4
cells. The number of infected cells was
scored as described under “Experimental
Procedures.” B, FBI-1-TatdMt reduced
the number of infectious HIV-1 virus par-
ticle by 286-fold compared with negative
control PHYK. The results are the aver-
ages of three independent experiments.
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4-1ZFC or FBI-1-TatdMt. FBI-1-TatdMt repressed transcrip-
tion five times more strongly as compared with the zinc finger
alone. Our data also suggest that although the zinc finger of
FBI-1 can repress transcription, the degree of transcription
repression can be significantly enhanced by a fusion with the
POZ domain and TatdMt (Fig. 3C).
Design of AZFs Recognizing Various Regions of HIV-1 LTR
and Transcription Repression—Because FBI-1 is ubiquitously
expressed and overexpression of the fusion protein in the tar-
geted cells can potentially alter the expression of various genes,
we designed and prepared ten artificial zinc fingers that
specifically recognized the HIV-1 LTR (Fig. 4, A and C). The
zinc fingers were designed to contain three or four zinc fin-
gers and to recognize 9 or 12 bp, respectively (Fig. 4C). Eight
of the ten zinc fingers were targeting the Sp1-binding region
(77 to 46 bp), and two others targeted the TATA box or
downstream region (37 to 66 bp) of the transcription start
point (Fig. 4A).
The zinc finger expression plasmids were cotransfected with
the TatWt expression plasmid into stable HeLa cells. Among
the AZFs we tested, AZF LTR-62 (recognizes CGGGACTGG)
and AZF LTR-65 (recognizes GGGCGGGAC) were stronger
transcription repressors than the others and repressed tran-
scription by 88–67%. AZF LTR-62 and -65 were selected for
further study (Fig. 5).
AZF LTR-62 and AZF LTR-65 Do Not Bind to the Putative
GC Box Recognized by Sp1 and Do Not Affect the Sp1-depend-
ent Transcription of the ADH5/FDH and p21Waf/Cip1
Genes—We investigated the specificity of AZF binding by
EMSA and transient transfection assays. Sp1 binds to the
putative GC box probe, and the Sp1-probe complex is super-
shifted by rabbit polyclonal antibody against Sp1 (Fig. 6A,
lanes 2 and 3). However, neither in vitro translated HA-tagged
AZF LTR-62 nor AZF LTR-65 bind to the GC box probe (Fig.
6A, lanes 5 and 7). AZF LTR-62 and AZF LTR-65 bind their
target sequence probes, and the complexes are supershifted by
antibody against HA tag (Fig. 6B). Once the AZF expression
plasmid and the human gene promoter are cotransfected into
HeLa cells, the AZFs do not affect the transcription of the two
well characterized Sp1-dependent human promoters, ADH5/
FDH and p21Waf/Cip1, suggesting that the AZFs act specifically
only on their own recognition sites (Fig. 6, C and D).
AZFs Targeted to Sp1-binding Region Can Repress the Tran-
scription Activation by Cyclin T1 and Sp1—It is interesting
that the two strong transcription repressors AZF LTR-62 and
AZF LTR-65 recognize the region around the Sp1-binding GC
box, one of the key regulatory elements of HIV-1 transcription
(19). Sp1 can activate transcription by interacting with cofac-
tors, the components of the general transcription machinery,
and cyclin T1 (20, 21). In particular, Sp1 binding and the
FIG. 3.Mapping of functional domains of FBI-1-TatdMT fusion
important in transcription repression. A, structures of various
deletion or mutant constructs of FBI-1-TatdMt fusion protein (construct
1-1). Deletion was made with the POZ domain, C terminus, nuclear
localization sequence (NLS), and junction domain between the POZ
domain and the zinc fingers. Mutations (marked with) are at the first
zinc finger. B, transient transfection assays in the stable HeLa cells.
Deletion or mutation of POZ domain, TatdMt, and zinc finger resulted
in a significant decrease in transcription repression. C, comparison of
the constructs showing low promoter activity, zinc finger itself with no
nuclear localization sequence, zinc finger plus C terminus (4-1ZFC),
and 1-1.
FIG. 4. Design of AZFs recognizing various regions of HIV-1
LTR and transcription repression. A, locations of ten artificial three
or four zinc finger-binding sites are indicated with dotted lines. The AZF
LTR-56 (II) is the only four zinc finger polypeptide. The zinc fingers
recognize a 9- or 12-bp nucleotide sequence. The numbers of the AZFs
are the uppermost nucleotide of the recognition site. The arrow (3) and
Tsp, transcription start point1. B, structure of the representative zinc
finger polypeptide composed of three artificial zinc fingers of the AZF
LTR-62. Shown are the fingers (F1, F2, and F3), the amino acids of each
finger critical in specific target recognition, and the nucleotide sequence
that each zinc finger recognizes. C, list of artificial zinc fingers, struc-
ture of fingers, and nucleotide sequences they recognize.
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interaction between Sp1-cyclin T1 are important for transcrip-
tion of HIV-1 LTR in the absence of Tat (Fig. 7A). We tested
whether the AZF or AZF-TatdMt fusion can repress transcrip-
tion contributed by the Sp1-cyclin T1 interaction. In stable
HeLa cells transfected with various expression vectors for cy-
clin T1, Sp1, AZF LTR-62, or POZ-AZF LTR-62-TatdMt fusion
proteins, cyclin T1 activated transcription by 5.5-fold, suggest-
ing that the molecular interaction does exist and is important
in the transcription activation in the absence of TatWt. The
transcription activation by Sp1 and cyclin T1 can be effectively
repressed by AZF LTR-62 or POZ-AZF LTR-62-TatdMt (Fig.
7B, lanes 2–4). Ectopic Sp1 slightly activates transcription over
the basal level, and cyclin T1 further activates it by 5-fold.
Transcription activation by cyclin T1 can be blocked by the AZF
LTR-62 alone and POZ-AZF LTR-62-TatdMt fusion (Fig. 7B,
lanes 6–8). The data suggests that the AZF LTR-62 bound at
the region around the Sp1-binding GC box inhibits Sp1-cyclin
T1-dependent transcription.
POZ domain, TatdMt Fusion Proteins of AZF LTR-62 and
AZF LTR-65 Potently Repress Transcription and HIV-1 Repli-
cation—We found that the functional domains important in
transcriptional repression by FBI-1-TatdMt are the POZ do-
main, zinc fingers, and TatdMt (Fig. 3). Fig. 5 showed that
although the AZF can repress transcription, it alone could not
repress transcription quite down to the basal level. Therefore,
we fused the POZ domain and TatdMt with AZF LTR-62 and
AZF LTR-65 and then tested their activities in transcription
repression (Fig. 8). The AZF alone can repress transcription
down to about 20% of the transcription level activated by
TatWt. By being fused with TatdMt, the fusion AZF became a
2–3-fold more potent transcription repressor. AZF LTR-62-
TatdMt or AZF LTR-65-TatdMt became even more potent re-
pressors after both were fused with the POZ domain, and they
completely nullified transcription activation by TatWt (Fig. 8B,
lanes 6 and 9).
We also performed trans-complementation HIV-1 viral rep-
lication inhibition assays using Magi cells as is described under
“Experimental Procedures” and Fig. 2A. The single round
transfection competent HIV-1 viruses were produced by the
cotransfection of recombinant HIV-1 genome defective in enve-
lope protein gene, VSV-G envelope protein gene and effector
POZ-AZF LTR-62 or -65-TatdMt expression plasmids or control
vector plasmid (pYHK) into the virus packaging 293T cells. The
viral supernatant was diluted and then used to infect the
HeLaT4 cells and to count the number of HeLaT4 cells infected
with HIV-1 virus; the cells were maintained in hygromycin-
containing medium. Although FBI-1-TatdMt potently inhibited
HIV-1 replication, both the POZ domain-AZF LTR-62-TatdMt
and POZ domain-AZF LTR-65-TatdMt inhibited replication
much more potently, by as much as 4,675-fold (Table I). Our
data suggest that the newly designed AZF LTR-TatdMt fusion
proteins are much more effective in replication inhibition com-
pared with FBI-1-TatdMt. Our data imply that once the fusion
expression plasmids are delivered to HIV-1-infected cells and
expressed effectively, the fusion protein can potently inhibit
HIV-1 virus transcription and replication.
FIG. 5. Transcription repression by the AZFs recognizing var-
ious regions of HIV-1 LTR. The ten zinc fingers were designed to bind
to the Sp1-binding region (77 to 46 bp), the TATA box, and the
downstream region (37 to 66 bp) of transcription start point. The
zinc finger expression plasmids were cotransfected with the TatWt
expression plasmid into stable HeLa cells integrated with HIV-1 LTR
fused with CAT reporter gene. Among the AZFs tested, AZF LTR-62
and AZF LTR-65 showed relatively stronger transcription repression
than the others.
FIG. 6. The AZFs do not bind the Sp1-binding GC box and do
not affect transcription of Sp1 dependent human gene promot-
ers, ADH5/FDH and p21Waf/Cip1. A, EMSA with [-32P]dCTP labeled
GC box probe. Sp1 binds to the probe, which is supershifted by antibody
against Sp1. Neither in vitro translated AZF LTR-62 nor AZF LTR-65
bind to the GC box probe. Control, control in vitro translated reticulo-
cyte extract. B, both in vitro translated HA-tagged AZF LTR-62 and
AZF LTR-65 bind to their own target [-32P]dCTP labeled oligonucleo-
tide probes and supershifted by HA antibody. C and D, neither AZF
LTR-62 nor AZF LTR-65 affect the transcription of the two well char-
acterized Sp1-dependent human gene promoters, ADH5/FDH and
p21Waf/Cip1. The arrows indicate retarded [-32P]dCTP-labeled oligonu-
cleotide probed bound by Sp1 or synthetic AZFs. The asterisk indicates
the supershifted protein-probe complex by antibody. Luc, luciferase.
The arrow and Tsp indicate the transcription start point 1.
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DISCUSSION
The molecular mechanism of the regulation of HIV-1 tran-
scription provides a molecular basis for developing novel anti-
viral agents. Based on the molecular mechanism of transcrip-
tion regulation on HIV-1 LTR, we developed artificial zinc
fingers targeted to the high affinity Sp1-binding site, and by
being fused with TatdMt and POZ domain, the zinc fingers
strongly block both Sp1-cyclin T1-dependent transcription and
Tat-dependent transcription, even in the presence of excess
expressed Tat.
Of the several key target sites on the HIV-1 LTR for designed
zinc fingers including ours, the most effective ones are the one
targeted to the Sp1-binding region located at 46 and 77
(relative to the RNA start site, 1) (2, 7, 8). The three Sp1-
binding sites are particularly importance in transcription (19).
The artificial zinc fingers developed by other researchers tar-
geted to the Sp1 sites are also very effective in transcription
repression, particularly by being fused with the repressor do-
main of KRAB or SID (2, 7, 8). In our case too, among the ten
zinc fingers designed, AZF LTR-62 and AZF LTR-65 targeted to
the GC box region were particularly effective transcription
repressors, both for the zinc finger alone and particularly in the
fusion form with POZ domain and TatdMt. Although the direct
comparison of the zinc finger in transcription repression is
difficult because investigators are using different assay sys-
tems and cell lines, the zinc fingers developed by us are also
quite potent repressors, and they nullify transcription and viral
replication as much as 4,675-fold. The binding sequences of
AZF LTR-62, and AZF LTR-65 are partially overlapping with
the Sp1-binding site but do not match precisely with Sp1-
binding sites of HIV-1 LTR. The AZFs do not recognize the GC
box recognized by Sp1 and do not alter expression of the genes
controlled by Sp1 such as ADH5/FDH and p21Waf/Cip1.
Sp1 bound at the proximal promoter of HIV-1 was shown to
interact with cyclin T1, and the interaction was important in
basal transcriptional activation of HIV-1 in the absence of Tat
(20, 21). We investigated whether AZF LTR-62 or -65 alone or
in fusion forms with the TatdMt could inhibit Sp1-cyclin T1-
dependent activation and found that the designed ZFs re-
pressed the activation contributed by the interaction. The data
may explain why the several zinc fingers targeted to the Sp1-
binding regions are quite efficient transcription repressors (2,
8). Although targeting the zinc finger adjacent to the middle
Sp1-binding site can effectively blocked transcription by Sp1
and cyclin T1, it may also be important to suppress the Sp1
FIG. 7. The AZF LTR-62 targeted adjacent to the middle Sp1-
binding site can repress the transcription activation contrib-
uted by cyclin T1 and Sp1 interaction. A, diagram on the role of
cyclin T1(), Sp1, and RNA polymerase II in the transcription activation
of HIV-1. Promoter-bound Sp1 recruits cyclin T1. Cyclin T1 and inter-
acting kinase phosphorylate the C-terminal domain (CTD) of RNA
polymerase II and activate transcription. B, transient transfection as-
says in stable HeLa cells. Transcription activation by Sp1 and cyclin T1
can be blocked by AZF or AZF fusion. Tsp, transcription start point; Pol
II, RNA polymerase II. FIG. 8. POZ domain, TatdMt fusion proteins of artificial zinc
fingers (AZF LTR-62 and AZF LTR-65) recognizing the Sp1-bind-
ing sites (62 to 54 bp and 65 to 57 bp) potently repress
transcription. A, structures of artificial zinc fingers, AZF-LTR-62,
AZF-LTR-65, and their fusions as compared with FBI-1-TatdMt (con-
struct 1-1). B, transient transfection assays in stable HeLa cells. Tran-
scription activation by TaWt can be repressed by AZF or AZF fusions.
POZ-AZF-LTR-62 or -LTR-65-TATdMt repressed transcription below
basal transcription level. NLS, nuclear localization sequence.
TABLE I
Inhibition of HIV-1 replication by TatdMt fusion proteins
of artificial zinc fingers
Expression plasmids encoding TatdMt fusion proteins of artificial
zinc fingers were cotransfected with a HIV-1 proviral DNA (YK177–86)
and a VSV-G expression plasmid, and virus-containing medium was
assayed for virus titration as described under “Experimental Proce-
dures.”
Effector plasmid Number of Hyg
r
colonies  S.D./ml
Fold
decrease
cfu/ml
pHYK (negative control) 3.6  0.7  105
FBI-TatMt 1.3  1.1  103 277
POZ-AZF LTR-62-TatMt 5.7  1.2  102 632
POZ-AZF LTR-65-TatMt 7.7  1.5  101 4,675
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activity sitting slightly upstream and downstream of the mid-
dle Sp1 site (66 to 57 bp). We have previously shown that
the POZ domain targeted proximal to the Sp1-binding site can
prevent the Sp1 binding because the POZ domain can interact
with incoming Sp1 and prevent the target recognition (9). Also,
POZ domain can interact with histone deacetylase and core-
pressors (mSin3A, NCoR/SMRT, and BCoR), and this interac-
tion can make nearby nucleosomes compact by recruited his-
tone deacetylase (22, 23). The nucleosome compaction around
the middle Sp1-binding site may prevent Sp1 and NF-B from
binding to the regulatory sequences. This may explain why the
AZF LTR-62 and LTR-65 are much more effective transcription
repressors by being fused with POZ domain and TatdMt.
No studies using AZF fusion have yet targeted the Tat-TAR
interaction, so we fused the above POZ-AZF fusions with the
polypeptide targeting this unique interaction, using TatdMt
that completely lacked interaction with cyclin-dependent pro-
tein kinase 9-cyclin T1, but it retained a good TAR binding
activity (12). The fusions were found to be potent repressors
both in transcription and replication probably by successful
blocking of transcription activation by both Sp1-cyclin T1 and
Tat-TAR-cyclin T1 interactions. Our AZF fusions are different
from other zinc fingers in that they contain Sp1 inhibiting the
POZ domain, a designer zinc finger, and a TatdMt. The AZF
fusions have been targeted specifically, and they completely
blocked both transcription of integrated HIV-1 viral gene and
replication. The fusions almost completely blocked the tran-
scription by Sp1, Tat, and cyclin T1. Accordingly, we suspect
that the transcription activation by NF-B will be also blocked
because basal transcription mainly contributed by Sp1 is es-
sentially blocked at the transcription initiation stage, as was
previously suggested by other zinc finger proteins targeting the
GC boxes (2, 7).
The zinc fingers developed by others and ourselves were
targeted to the key regulatory elements of HIV-1 gene ex-
pression. The key regulatory elements are critical for viral
transcription and replication and less likely to have mutation
in the region. For example, base substitution mutations tar-
geted to one or all three Sp1-binding sites were found both to
eliminate the binding of Sp1 and to cause up to a 10-fold
reduction in transcriptional efficiency in vitro (19). Moreover,
HIV-1 viruses with mutation in the critical regions such as
the high affinity Sp1-binding GC box and TAR are not likely
to be replication-competent. If there is a HIV-1 subtype with
mutation in the region we are targeting, it will be still pos-
sible to design a new artificial zinc finger and repress tran-
scription effectively by incorporating the POZ domain and
TatdMt. However, the development of resistance to zinc fin-
ger transcription factors can also be anticipated, and an
effective therapeutic strategy based on ZF may require the
delivery of multiple transcription factors.
Highly active antiretroviral therapy is a highly effective in
the treatment of HIV-1 disease. However, virus resistance,
toxicity, side effects, and patient compliance are problematic
for many HIV-1 patients (Ref. 24 and references therein). Al-
though the effects of highly active antiretroviral therapy are
often immediate and profound, the virus is not eliminated
completely, and latently infected cells do persist (25, 26). Virus
replication rebounds rapidly after drug withdrawal. The other
therapeutic strategies such as inhibition of viral transcription
such as antisense oligonucleotides, small interference RNA
(27–29), and ribozymes (30, 31) have long been recognized as an
important goal in HIV-1 therapy. In this study, based on the
molecular mechanism of interaction among regulatory pro-
teins, DNA, and RNA, we developed novel zinc finger fusion
proteins that can inhibit transcription. The designed zinc fin-
gers approach targeting the transcription mechanism involving
Sp1, GC boxes, cyclin T1, and Tat-TAR interaction may repre-
sent a highly effective alternative therapy for HIV infection,
along with the development of novel means of specific gene
delivery to the HIV-1-infected cells. Our work extends recent
studies by Reynolds et al. (2) and Segal et al. (8), and this work
is unique in that we take full advantage of the Sp1-inhibiting
POZ domain and the dominant negative mutant form of Tat.
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